Biontech SE Form 4 insider transactions

BioNTech SE's Chief Financial Officer, Ramon Zapata Gomez, has reported the acquisition of stock options and performance share units.

BioNTech SE reports on May 12, 2026, that Chief Legal Officer and Chief Business Officer Ryan James Timothy Patrick was granted stock options and performance share units.

BioNTech SE Chief Operating Officer Sierk Poetting has acquired company shares and performance units through option exercises and PSU grants.

BioNTech SE reports the grant of stock options and performance share units to Chief People Officer Kylie Jimenez.

BioNTech SE Chief Operating Officer Sierk Poetting has sold 50,000 ordinary shares through a pre-arranged 10b5-1 trading plan.

BioNTech SE announced the successful satisfaction of the minimum condition for its exchange offer for CureVac N.V., with 81.74% of shares tendered.

BioNTech announced CureVac shareholders overwhelmingly approved its exchange offer, setting the stage for the acquisition's completion with a defined exchange ratio.

BioNTech's third-quarter revenue surged 22% driven by a significant out-licensing deal with Bristol-Myers Squibb, despite a decline in COVID-19 vaccine sales and a confirmed full-year net loss outlook.

BioNTech SE updated its public exchange offer for CureVac N.V. shares and reported a net loss of €28.7 million for Q3 2025, driven by settlement expenses and declining COVID-19 vaccine revenues, despite strategic partnership gains.

BioNTech SE has initiated its exchange offer to acquire all outstanding shares of CureVac N.V. as part of a previously announced transaction.

BioNTech SE has commenced its public exchange offer to acquire all outstanding shares of CureVac N.V. for an implied aggregate equity value of approximately $1.25 billion, aiming to bolster its mRNA-based cancer immunotherapy pipeline.

BioNTech SE announces an all-stock offer to acquire CureVac N.V., aiming to significantly expand its mRNA-based oncology and infectious disease capabilities, despite projecting a net loss for 2025.

BioNTech SE launches an exchange offer to acquire all issued ordinary shares of CureVac N.V. in a stock-for-stock transaction, aiming to expand its mRNA oncology capabilities.

BioNTech SE has reached comprehensive settlement arrangements with CureVac and GSK, resolving global patent litigation related to mRNA COVID-19 vaccines and securing key licenses, contingent on its acquisition of CureVac.

BioNTech resolves patent litigation with CureVac and GSK, securing a non-exclusive license for mRNA products, alongside its planned acquisition of CureVac.

BioNTech SE has announced a definitive agreement to acquire CureVac N.V. through a public exchange offer, leading to CureVac's delisting and full integration into BioNTech's operations.

BioNTech SE announced its definitive agreement to acquire all shares of CureVac N.V., aiming to strengthen its mRNA-based cancer immunotherapy development and accelerate innovative cancer treatments.

BioNTech SE has announced a definitive Purchase Agreement to acquire all shares of CureVac N.V., a strategic move aimed at strengthening its mRNA-based cancer immunotherapy programs and integrating CureVac's research and manufacturing site.

BioNTech SE has announced its intent to acquire CureVac N.V. through an exchange offer valued at approximately $1.25 billion, aiming to bolster its mRNA capabilities and pipeline.

BioNTech SE has filed pre-commencement communications with the SEC regarding its proposed acquisition of CureVac N.V. through an exchange offer, outlining the procedural steps and associated risks.

BioNTech SE announced a definitive agreement to acquire CureVac N.V. in an all-stock transaction valued at approximately $1.25 billion, aiming to significantly strengthen its mRNA-based cancer immunotherapy capabilities.